XENE Xenon Pharmaceuticals Inc.

9.9
+0.05  (+1%)
Previous Close 9.85
Open 9.78
Price To Book 3.02
Market Cap 255152690
Shares 25,772,999
Volume 72,911
Short Ratio
Av. Daily Volume 92,782

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2H 2020.
XEN1101
Adult focal seizures
Phase 2 data released March 24, 2017 - endpoints not met.
XEN801
Acne
Phase 2b data released June 27, 2017. Endpoints not met.
TV-45070
Postherpetic neuralgia
Phase 2b trial did not meet endpoints - July 2015
TV-45070
Osteoarthritis
Phase 2 trial to be initiated 2019.
XEN901
Pediatric epilepsy
Phase 3 trial to be initiated following IND filing 4Q 2019.
XEN496
Epilepsy

Latest News

  1. Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Overpaying Its CEO?
  2. Xenon Pharmaceuticals Inc. (XENE) Q1 2019 Earnings Call Transcript
  3. Edited Transcript of XENE earnings conference call or presentation 7-May-19 8:30pm GMT
  4. Xenon Pharmaceuticals: 1Q Earnings Snapshot
  5. Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
  6. Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
  7. Xenon Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
  8. Xenon Pharmaceuticals Inc. (NASDAQ:XENE): Immense Growth Potential?
  9. Edited Transcript of XENE earnings conference call or presentation 6-Mar-19 9:30pm GMT
  10. Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update
  11. Xenon Pharmaceuticals Inc. to Host Earnings Call
  12. The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split
  13. Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update
  14. Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
  15. Xenon Provides Key Regulatory Updates on XEN007 and XEN1101
  16. What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock?
  17. Xenon Pharmaceuticals Outlines 2019 Key Milestones
  18. Eversept Partners’ Return, AUM, and Holdings
  19. Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock?
  20. Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting